The estimated Net Worth of Mark Murcko is at least $8.55 Milión dollars as of 8 September 2022. Dr Murcko owns over 25,000 units of Relay Therapeutics stock worth over $7,736,348 and over the last 4 years he sold RLAY stock worth over $748,750. In addition, he makes $65,750 as Co-Founder & Director at Relay Therapeutics.
Dr has made over 2 trades of the Relay Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of RLAY stock worth $748,750 on 8 September 2022.
The largest trade he's ever made was selling 25,000 units of Relay Therapeutics stock on 8 September 2022 worth over $748,750. On average, Dr trades about 8,333 units every 130 days since 2020. As of 8 September 2022 he still owns at least 996,952 units of Relay Therapeutics stock.
You can see the complete history of Dr Murcko stock trades at the bottom of the page.
Dr. Mark Murcko Ph.D. is the Co-Founder & Director at Relay Therapeutics.
As the Co-Founder & Director of Relay Therapeutics, the total compensation of Dr D at Relay Therapeutics is $65,750. There are 4 executives at Relay Therapeutics getting paid more, with Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS having the highest compensation of $1,016,803.
Dr D is 61, he's been the Co-Founder & Director of Relay Therapeutics since . There are no older and 6 younger executives at Relay Therapeutics.
Mark's mailing address filed with the SEC is C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Relay Therapeutics have traded over $234,228,237 worth of Relay Therapeutics stock and bought 110,000 units worth $2,200,000 . The most active insiders traders include Rock Ventures Iii, L.P.Thir..., Sanjiv Patel a Donald A Bergstrom. On average, Relay Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $406,570. The most recent stock trade was executed by Thomas Catinazzo on 29 July 2024, trading 10,780 units of RLAY stock currently worth $92,277.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics executives and other stock owners filed with the SEC include: